{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/psoriasis/management/scalp-psoriasis/","result":{"pageContext":{"chapter":{"id":"6a7e9d56-0d17-5c90-b835-822367fbcd3e","slug":"scalp-psoriasis","fullItemName":"Scenario: Scalp psoriasis","depth":2,"htmlHeader":"<!-- begin field 8ae982e6-d6de-4282-877c-1843896f552b --><h2>Scenario: Scalp psoriasis</h2><!-- end field 8ae982e6-d6de-4282-877c-1843896f552b -->","summary":"Covers the management of scalp psoriasis in primary care.","htmlStringContent":"<!-- begin item 70ba5f46-fb00-4b39-be51-293f3f02c6c8 --><!-- begin field 123b590a-4006-49df-a4be-acbc015bb2b8 --><p>From age 18 years onwards.</p><!-- end field 123b590a-4006-49df-a4be-acbc015bb2b8 --><!-- end item 70ba5f46-fb00-4b39-be51-293f3f02c6c8 -->","topic":{"id":"a3ecec3a-acde-5ece-90b0-dedc6c08db8b","topicId":"c8702cb0-6f30-44e4-832b-ab9161ee384a","topicName":"Psoriasis","slug":"psoriasis","lastRevised":"Last revised in December 2020","chapters":[{"id":"d0c39045-d8df-5a7e-bd7d-96fef3aefc3a","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"6e22adaa-de33-5d1c-bc1f-9740d238c5a2","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a7c9da10-9760-5143-bf20-167f1e832103","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"409aaeee-7f7b-53cc-afdc-9ea9034984d6","slug":"changes","fullItemName":"Changes"},{"id":"1677a6dc-645a-58fe-8ed8-8bdfcface768","slug":"update","fullItemName":"Update"}]},{"id":"ca38cddf-4680-5dc4-a0df-79ab9910a789","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fc350387-9e56-5f4b-b454-3cfa5ecd9a2a","slug":"goals","fullItemName":"Goals"},{"id":"00a9f2b3-e7b5-5394-9762-48d34a0dc722","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"400cbb71-cb76-5ee3-824a-738bc6249b3b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"ad046045-038c-5b75-8f42-50343d5b824e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"773d3740-99b6-5a32-b555-968b2efb0b8b","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"0692cf2f-4b3d-5098-afe3-ac07b3c763ff","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"d16fcd88-1021-5238-86e4-2452eee7fdde","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"ef476810-392e-5b83-b527-fe921221cc0b","slug":"definition","fullItemName":"Definition"},{"id":"fb1e0af3-fd46-562a-83d6-33a31640b639","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d6b8dab4-762f-5e9e-a83e-35a3652483b3","slug":"trigger-factors","fullItemName":"Trigger factors"},{"id":"70837c8d-73ae-5bc4-a042-949d31503ca3","slug":"associated-conditions","fullItemName":"Associated conditions"},{"id":"e90f3736-0e28-53fa-8295-309df8aa8e00","slug":"complications","fullItemName":"Complications"},{"id":"9523ad16-6e73-50ba-94bd-64c548f5c313","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"4d0deda5-f89f-59e7-8978-1c3337afdcfe","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"067d150c-d6d4-5992-9319-f86bfeecca88","slug":"assessment","fullItemName":"Assessment"},{"id":"58b4da96-dda6-596b-9570-fd5070898cfe","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"27af05e5-54bf-5bc5-ba76-d1b8f18e7252","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","fullItemName":"Management","slug":"management","subChapters":[{"id":"82ee7501-0589-54c2-8df7-5a9256a3f1d0","slug":"pustular-or-erythrodermic-psoriasis","fullItemName":"Scenario: Pustular or erythrodermic psoriasis"},{"id":"e4183760-c129-567e-9211-cef27ef68100","slug":"trunk-limbs","fullItemName":"Scenario: Trunk and limbs"},{"id":"6a7e9d56-0d17-5c90-b835-822367fbcd3e","slug":"scalp-psoriasis","fullItemName":"Scenario: Scalp psoriasis"},{"id":"9c7cebad-a77f-5fa8-811a-50815577a51c","slug":"facial-flexural/genital-psoriasis","fullItemName":"Scenario: Facial/flexural/genital psoriasis"},{"id":"6fbadcef-730e-5874-97ad-53e1f12bd5e3","slug":"guttate-psoriasis","fullItemName":"Scenario: Guttate psoriasis"},{"id":"a069495e-d2fe-5fca-9799-1b5f4f874033","slug":"nail-psoriasis","fullItemName":"Scenario: Nail psoriasis"},{"id":"08dc9427-b5ec-59f4-b47b-72a666beacef","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ce3be64b-a968-59e2-b206-5a055de98330","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"520d3bb6-49cf-5f46-b761-9df1c712ad28","slug":"emollients","fullItemName":"Emollients"},{"id":"2a68bcd1-b92f-579a-955e-f4638d00073f","slug":"vitamin-d-preparations","fullItemName":"Vitamin D preparations"},{"id":"39f1a594-6e44-59b9-bb85-a277475d7386","slug":"salicylic-acid","fullItemName":"Salicylic acid"},{"id":"325d4c77-192a-5152-971f-a5f4f1d64fc7","slug":"coal-tar-products","fullItemName":"Coal tar products"},{"id":"302b90f5-e0d6-53cc-88ce-6a06def02b51","slug":"dithranol-short-contact","fullItemName":"Dithranol (short-contact)"}]},{"id":"00678b76-cc05-5d69-a6be-8760727fb9cf","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"91ae130b-06c7-538c-a295-af4bf7a3dbf1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"358d84df-224b-5d6b-96cd-c52dfe00a200","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"383c93f2-ae1f-5c75-af43-3a9a448c1669","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"3703e9fb-0103-5fe6-a0ed-192226578ed6","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d248a57f-2b73-5c2f-89c5-18ed618c3535","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"e35fcef8-37a3-5afe-9250-f527d2c6e017","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"7314bc52-4cb9-530c-a905-917edad0de05","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"eaab9e94-c74e-5c84-ba14-d8db3a6dd1e8","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"06ed4994-9ab0-50c7-9f28-1e428c22b7c0","slug":"management","fullItemName":"Management","depth":3,"htmlHeader":"<!-- begin field 2b6de8c8-e737-4790-91d3-97884a4fc735 --><h3>How should I manage scalp psoriasis?</h3><!-- end field 2b6de8c8-e737-4790-91d3-97884a4fc735 -->","summary":null,"htmlStringContent":"<!-- begin item 77ed2a59-c340-442a-b1d6-7e457d80cd87 --><!-- begin field 3b22aa44-95f2-4279-9d4b-aa59cb196a8a --><p><strong>If the person has <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#scalp-psoriasis\">scalp psoriasis</a>:</strong></p><ul><li>Offer advice on the nature of psoriasis, and explain that treatment is aimed at control of symptoms rather than cure, and that complete clearance of skin lesions may not be possible.</li><li>Reassure that it is not an infectious condition, and provide advice on sources of information and support, such as:<ul><li>The Psoriasis and Psoriatic Arthritis Alliance (PAPAA; website available at <a data-hyperlink-id=\"ef1a0534-11de-4d12-860e-a93100a4c232\" href=\"http://www.papaa.org/\" target=\"_blank\">www.papaa.org</a>) is a national charity which provides information and advice on all aspects of psoriasis and psoriatic arthritis, including a leaflet on <a data-hyperlink-id=\"e90dcf35-08b6-42d3-bb53-a93100a4c327\" href=\"http://www.papaa.org/sites/default/files/scalp%20psoriasis%20final.pdf\" target=\"_blank\">Scalp psoriasis</a>.</li><li>The Psoriasis Association (website available at <a data-hyperlink-id=\"00182530-7ebd-44f0-89c6-a93100a4c47b\" href=\"https://www.psoriasis-association.org.uk/\" target=\"_blank\">www.psoriasis-association.org.uk</a>) is a national charity and membership organization for people affected by psoriasis, which provides a leaflet on <a data-hyperlink-id=\"adb7ad8b-a099-46ce-84b0-a93100a4c48a\" href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/SCALP_2016.pdf\" target=\"_blank\">Scalp psoriasis</a>.</li></ul></li><li>Give general lifestyle advice to reduce the risk of exacerbations, such as advice on:<ul><li>Smoking cessation if appropriate. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a> for more information.</li><li>Drinking alcohol within recommended limits. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a> for more information.</li><li>Weight loss if the person is overweight or obese. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a> for more information. The PAPAA has an information leaflet on <a data-hyperlink-id=\"c33cd688-88da-485b-bde3-a93100a4c48e\" href=\"http://www.papaa.org/sites/default/files/Psoriatic_lifestyle_and_nutrition.pdf\" target=\"_blank\">Psoriatic lifestyle and nutrition</a>.</li></ul></li><li>Assess for associated stress, distress, anxiety and/or depression, and manage appropriately. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/generalized-anxiety-disorder/\">Generalized anxiety disorder</a> and <a class=\"topic-reference external-reference\" href=\"/topics/depression/\">Depression</a> for more information.<ul><li>The PAPAA has an information leaflet on <a data-hyperlink-id=\"84245dd2-64c9-4bac-b6f5-a93100a4c493\" href=\"http://www.papaa.org/sites/default/files/Psychological%20aspects%20of%20psoriasis%20final%20May%202015.pdf\" target=\"_blank\">Psychological aspects of psoriasis</a>.</li></ul></li><li>Offer treatment with <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/scalp-psoriasis/#topical-drug-treatment\">topical preparations</a>, depending on the person's preferences, cosmetic acceptability, practical aspects of application, and the site(s) and extent of psoriasis to be treated.<ul><li>The PAPAA has an information leaflet on <a data-hyperlink-id=\"7ae31fb6-4bf1-4869-b931-a93100a4c499\" href=\"http://www.papaa.org/sites/default/files/Treatments_Psoriasis_2017.pdf\" target=\"_blank\">Treatments for psoriasis: an overview</a>.</li><li>The British Association of Dermatologists has an information leaflet on <a data-hyperlink-id=\"01a89fc0-3c91-4567-a09f-a93100a4c4a1\" href=\"http://www.bad.org.uk/shared/get-file.ashx?id=123&itemtype=document\" target=\"_blank\">Topical treatments for psoriasis</a>.</li><li>Advise that topical treatments may take several weeks to start to work, and if treatment is stopped suddenly, there may be a risk of relapse.<ul><li>Lotions, solutions or gels are suitable for the scalp or hair-bearing areas.</li></ul></li><li>Topical corticosteroids are only suitable for treating localized areas of psoriasis. Note: repeat prescriptions for topical corticosteroids should be carefully reviewed and supervised to identify any adverse effects, and to avoid use on widespread psoriasis where there is a risk of unstable disease.</li></ul></li><li>Arrange to review the person within four weeks after treatment has started and regularly thereafter, depending on clinical judgement, to:<ul><li>Assess the initial response to treatment, including the <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/assessment/\">severity and impact</a> of psoriasis.</li><li>Assess for any issues with topical application or adverse effects.</li><li>Reinforce the importance of adherence to treatments.</li></ul></li><li>Advise the person to seek urgent medical advice if they experience unexplained joint pain or swelling, as this may be a sign of <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/background-information/associated-conditions/\">psoriatic arthritis</a> that requires specialist referral.</li><li>Arrange to review the person at least annually if they are using multiple courses of potent- or very-potent topical corticosteroids to:<ul><li>Optimize treatment and assess for adverse effects such as skin atrophy. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a> for more information.</li><li>Assess disease <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/assessment/\">severity and impact</a>, and assess for new joint symptoms that may suggest psoriatic arthritis, and arrange specialist referral if appropriate.</li><li>Note: seek urgent specialist dermatology advice if there is any uncertainty about adverse effects or drug safety if the person is taking <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/trunk-limbs/#specialist-assessment-management\">specialist drug treatments</a>.</li></ul></li><li>Assess the person's risk of cardiovascular disease at least every five years, especially if psoriasis is severe, depending on clinical judgement. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a> for more information.<ul><li>The PAPAA has an information leaflet on <a data-hyperlink-id=\"01033667-8139-44d2-b35e-a93100a4c4aa\" href=\"http://www.papaa.org/sites/default/files/Ps%20and%20the%20heart%20final.pdf\" target=\"_blank\">Psoriasis and the heart</a>.</li></ul></li></ul><!-- end field 3b22aa44-95f2-4279-9d4b-aa59cb196a8a --><!-- end item 77ed2a59-c340-442a-b1d6-7e457d80cd87 -->","subChapters":[{"id":"ac8f9083-d93f-578b-a333-ddbda817c947","slug":"basis-for-recommendation-160","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e0cb96cc-9c05-41ac-b9b6-e812caca364d --><h4>Basis for recommendation</h4><!-- end field e0cb96cc-9c05-41ac-b9b6-e812caca364d -->","summary":null,"htmlStringContent":"<!-- begin item 1605b0b9-40ee-488d-b02b-7af6e73ca6e3 --><!-- begin field 21fca403-8545-474d-9425-9d49d57503b3 --><p>The recommendations on management are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>], the Scottish Intercollegiate Guidelines Network (SIGN) clinical guideline <em>Diagnosis and management of psoriasis and psoriatic arthritis in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>], a concise guideline on psoriasis convened by NICE in association with the Royal College of Physicians [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>], a systematic review on weight loss intervention on disease severity of psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Upala, 2015</a>], and expert opinion in review articles on psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Cohen, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Boehncke, 2015</a>].</p><h5>Giving lifestyle advice</h5><ul><li>The recommendation on lifestyle and weight loss advice is based on a systematic review of five randomized controlled trials (RCTs; number of participants not specified) which found strong evidence of a greater reduction in psoriasis severity scores in overweight or obese people receiving weight loss intervention (by diet or exercise) than a control group. The meta-analysis was limited, however, by the small number of included studies, the short follow-up period, and heterogeneity between studies [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Upala, 2015</a>].</li></ul><h5>Arranging annual review</h5><ul><li>The recommendations on annual review are largely based on the SIGN clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>].</li><li>The recommendation on seeking specialist dermatology advice if there is any uncertain about safety or appropriateness of specialist drug treatment is pragmatic, based on what CKS considers to be good clinical practice.</li></ul><h5>Assessing cardiovascular disease risk</h5><ul><li>People with severe psoriasis are at increased cardiovascular risk, so these people should be screened using appropriate risk assessment tools to allow early management of modifiable risk factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Boehncke, 2015</a>].</li></ul><!-- end field 21fca403-8545-474d-9425-9d49d57503b3 --><!-- end item 1605b0b9-40ee-488d-b02b-7af6e73ca6e3 -->","subChapters":[]}]},{"id":"4049e73a-fe4e-51ac-8b18-0f085f925f58","slug":"topical-drug-treatment","fullItemName":"Topical drug treatment","depth":3,"htmlHeader":"<!-- begin field 4b7088d6-7a0d-44b2-8050-2fc496bc4664 --><h3>What topical drug treatments should I offer?</h3><!-- end field 4b7088d6-7a0d-44b2-8050-2fc496bc4664 -->","summary":null,"htmlStringContent":"<!-- begin item 65809ac8-d3e8-41c2-b893-fec515c1912c --><!-- begin field 2e564fc7-9910-4dd2-8d77-3c788bd2bf2f --><ul><li><strong>Offer treatment with topical preparations, and consider whether <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/scalp-psoriasis/#referral\">referral</a> is needed if lesions are extensive, severe, or not responding to treatment. Options include:</strong><ul><li>A potent topical corticosteroid (applied once a day). See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a> for more information.<ul><li>Give advice on how to minimize the risk of corticosteroid adverse effects, such as stopping the topical corticosteroid once the psoriasis is clear or nearly clear.</li><li>Provide advice on sources of information such as the Psoriasis Association leaflet on <a data-hyperlink-id=\"eb6b1c49-fd07-425d-8f9c-a931009fe1bc\" href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Steroids.pdf\" target=\"_blank\">Topical steroids</a>.</li></ul></li><li>If corticosteroids are not tolerated, or if there is mild to moderate scalp psoriasis, consider treatment with a vitamin D preparation alone (applied once a day). See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/vitamin-d-preparations/\">Vitamin D preparations</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/\">Prescribing information</a> for more information.<ul><li>Provide advice on sources of information such as the Psoriasis Association leaflet on <a data-hyperlink-id=\"536e0a9e-b380-4bb7-964d-a931009fe21f\" href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Vitamin_D.pdf\" target=\"_blank\">Vitamin D</a>.</li></ul></li><li>A coal tar shampoo, but this should <em>not </em>be used alone for people who have severe scalp psoriasis. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/coal-tar-products/\">Coal tar products</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/\">Prescribing information</a> for more information.<ul><li>Provide advice on sources of information such as the Psoriasis Association leaflet on <a data-hyperlink-id=\"3234ee93-b6c4-4696-b5f2-a931009fe229\" href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Coal_Tar.pdf\" target=\"_blank\">Coal Tar Applications</a>.</li></ul></li></ul></li><li><strong>Review the person after four weeks:</strong><ul><li>If there has been a good initial response, continue topical treatment until the skin is clear or nearly clear.</li><li>Advise the person <em>not </em>to apply potent corticosteroids for more than eight weeks at any one site.<ul><li>Treatment may be restarted after a four-week 'treatment break'.</li></ul></li><li>Advise that courses of topical treatments (including corticosteroids) can be used as needed to maintain satisfactory control of psoriasis, reinforcing the advice on the safe use of potent topical corticosteroids.<ul><li>Offer a prescription for topical treatments to allow self-management on an as-needed basis.</li></ul></li></ul></li><li><strong>If there is a poor initial response to treatment after the first four weeks:</strong><ul><li>Check adherence to treatment, and ask about any issues with application, cosmetic acceptability, or tolerability of topical treatments.</li><li>If there is no obvious explanation for treatment failure, consider:<ul><li>A different topical formulation of a potent corticosteroid such as a shampoo or mousse <em>and/or</em></li><li>A scalp treatment such as salicylic acid, olive oil, coconut oil, arachis oil, or an emollient to remove thick scale (before further applications of the potent corticosteroid).</li><li>Provide advice on sources of information such as the Psoriasis Association leaflet on <a data-hyperlink-id=\"985496b3-10be-47d7-8aae-a931009fe22d\" href=\"https://www.psoriasis-association.org.uk/media/InformationSheets/Moisturisers.pdf\" target=\"_blank\">Moisturisers</a>.</li></ul></li></ul></li><li><strong>If there is a poor response after an additional four weeks, offer:</strong><ul><li>A combined topical preparation containing a potent corticosteroid and vitamin D (applied once a day for up to four weeks) <em>or</em></li><li>A vitamin D preparation applied once a day (only for people who cannot tolerate corticosteroids and have mild to moderate scalp psoriasis).</li></ul></li><li><strong>If there is still a poor response after up to eight weeks of treatment:</strong><ul><li>Consider whether there may be an <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/differential-diagnosis/\">alternative diagnosis</a>, and manage appropriately.</li><li>Consider prescribing a very-potent corticosteroid applied up to twice a day for two weeks. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/corticosteroids-topical-skin-nose-eyes/\">Corticosteroids - topical (skin), nose, and eyes</a> for more information, <em>or</em></li><li>Consider prescribing a coal tar preparation applied once or twice a day. See the section on <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/coal-tar-products/\">Coal tar products</a> in <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/prescribing-information/\">Prescribing information</a> for more information.</li><li>Arrange <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/scalp-psoriasis/#referral\">referral</a> to a dermatologist for specialist assessment and management.</li></ul></li></ul><!-- end field 2e564fc7-9910-4dd2-8d77-3c788bd2bf2f --><!-- end item 65809ac8-d3e8-41c2-b893-fec515c1912c -->","subChapters":[{"id":"0d7e3a6a-3cbd-57ee-81b8-b92091bb5d6b","slug":"basis-for-recommendation-a07","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field d2abc0ed-a7d0-4a2c-865c-32fcd78f4757 --><h4>Basis for recommendation</h4><!-- end field d2abc0ed-a7d0-4a2c-865c-32fcd78f4757 -->","summary":null,"htmlStringContent":"<!-- begin item a07ce494-b675-44a7-b047-b56241490886 --><!-- begin field 59a90a7a-e2c4-4872-be52-492558e9512f --><p>The recommendations on topical drug treatments are largely based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>], the Scottish Intercollegiate Guidelines Network (SIGN) clinical guideline <em>Diagnosis and management of psoriasis and psoriatic arthritis in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>], a Cochrane systematic review <em>Topical treatments for scalp psoriasis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Schlager, 2016</a>], and expert opinion in review articles on psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Cohen, 2012</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Boehncke, 2015</a>].</p><h5>Choice of topical preparations</h5><ul><li>The recommendations on the choice and sequencing of active topical treatments are largely based on a clinical and cost-effectiveness analysis in the NICE clinical guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>].<ul><li>It concluded that initial treatment with potent- or very-potent corticosteroids is cost-effective in the treatment of scalp psoriasis, however NICE recognized the increased risk of adverse effects with very-potent corticosteroids, and therefore it recommends a trial of potent corticosteroids first-line.</li><li>NICE ranked topical vitamin D preparations as the next cost-effective strategy following the use of potent corticosteroids, and reserved very-potent corticosteroids as a third-line option if other topical treatments have not improved symptoms, in order to minimize the risk of adverse effects.</li><li>NICE found that coal tar-based shampoos were only marginally more effective than placebo or vehicle scalp solution and were less effective than other topical scalp treatments. As a result, they are not recommended as the only topical treatment for severe scalp psoriasis as they are unlikely to be clinically effective or cost-effective.</li></ul></li><li>This contrasts with the SIGN clinical guideline which recommends overnight application of tar preparations, salicylic acid, or oil preparations to remove thick scale [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>].</li><li>A Cochrane systematic review of 59 randomized controlled trials (RCTs; n = 11,561) found moderate-quality evidence that in terms of clearance and treatment response, corticosteroids were more effective than vitamin D preparations, and two-compound combination therapy with corticosteroid and vitamin D was more effective than vitamin D alone. It concluded that corticosteroid monotherapy and combination therapy had similar safety profiles and there was only a small benefit of combination therapy over corticosteroid monotherapy, therefore corticosteroid monotherapy 'may be fully acceptable for short-term therapy' [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Schlager, 2016</a>].<ul><li>A systematic review cited in the Cochrane review concluded that combination therapy with corticosteroid and vitamin D offered a small advantage over corticosteroid monotherapy, and this might be a treatment option in treatment-resistant scalp psoriasis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Mason, 2013a</a>].</li></ul></li><li>The recommendation on the use of the keratolytic agent salicylic acid is based on the fact that this reduces thick scale to allow other treatments to penetrate the skin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Cohen, 2012</a>].<ul><li>A systematic review cited in the Cochrane review concluded that there was no evidence to support the first-line use of a tar-based product such as shampoo (with or without a keratolytic, such as salicylic acid) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Mason, 2013a</a>].</li></ul></li></ul><!-- end field 59a90a7a-e2c4-4872-be52-492558e9512f --><!-- end item a07ce494-b675-44a7-b047-b56241490886 -->","subChapters":[]}]},{"id":"5aef960c-2f6e-5680-b09f-3153589b39ff","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field 191887a6-7223-45a5-a929-c0e5a5852ab7 --><h3>When should I refer a person with scalp psoriasis?</h3><!-- end field 191887a6-7223-45a5-a929-c0e5a5852ab7 -->","summary":null,"htmlStringContent":"<!-- begin item fc2cca54-2ec5-4709-899e-7b861a811001 --><!-- begin field 3f74d4c0-6af5-4e44-98b5-be4f1b047e2d --><ul><li>If the person presents with suspected <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#pustular-psoriasis\">generalized pustular psoriasis</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/diagnosis/#erythrodermic-psoriasis\">erythrodermic psoriasis</a>, this should be managed as a medical emergency:<ul><li>Arrange for urgent same-day specialist dermatology assessment and ongoing management.</li></ul></li><li>Arrange referral to a dermatologist for <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/trunk-limbs/#specialist-assessment-management\">specialist assessment and management</a>, the urgency depending on clinical judgement, if:<ul><li>There is uncertainty about the diagnosis.</li><li>Psoriasis is extensive, for example more than 10% of the <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/assessment/\">body surface area</a> is affected.</li><li>Psoriasis is at least moderately severe, as measured by the <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/diagnosis/assessment/\">Physician&#39;s Global Assessment</a> tool.</li><li>Psoriasis is resistant to <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/management/scalp-psoriasis/#topical-drug-treatment\">topical drug treatments</a> in primary care, or treatments are not tolerated.</li><li>There is a significant impact on the person's physical, psychological, or social wellbeing.</li><li>Additional information or education is needed (for example about application of topical treatments).</li></ul></li><li>Arrange an urgent referral to a rheumatologist if a diagnosis of <a class=\"topic-reference internal-reference\" href=\"/topics/psoriasis/background-information/associated-conditions/\">psoriatic arthritis</a> is suspected.</li></ul><!-- end field 3f74d4c0-6af5-4e44-98b5-be4f1b047e2d --><!-- end item fc2cca54-2ec5-4709-899e-7b861a811001 -->","subChapters":[{"id":"e670367b-8e67-59e9-b1b5-3dcab6034be5","slug":"basis-for-recommendation-71f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field db6043d0-1723-4179-990f-1d340d57139b --><h4>Basis for recommendation</h4><!-- end field db6043d0-1723-4179-990f-1d340d57139b -->","summary":null,"htmlStringContent":"<!-- begin item 71ffd7ce-9d92-4f66-bce5-cf3958918395 --><!-- begin field 92103e9d-2002-49d7-b7ed-83c0aefc0a3f --><p>The recommendations on referral are based on the National Institute for Health and Care Excellence (NICE) clinical guideline <em>Psoriasis: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">NICE, 2017</a>], the Scottish Intercollegiate Guidelines Network (SIGN) clinical guideline <em>Diagnosis and management of psoriasis and psoriatic arthritis in adults</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>], and a concise guideline on psoriasis convened by NICE in association with the Royal College of Physicians [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>].</p><ul><li>The recommendation on arranging urgent referral to rheumatology if psoriatic arthritis is suspected is based on the fact that an early diagnosis should be made to reduce the risk of erosive and progressive joint damage and loss of function [<a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">SIGN, 2010a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/psoriasis/references/\">Samarasekera, 2014</a>].</li></ul><!-- end field 92103e9d-2002-49d7-b7ed-83c0aefc0a3f --><!-- end item 71ffd7ce-9d92-4f66-bce5-cf3958918395 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}